Aperta Biosciences
Developing novel treatments for ocular surface diseases. Lead program, APT-001 (spinosad), is currently being evaluated in a Phase 2 clinical trial for the treatment chronic blepharitis.
Building the Future of Life Sciences
Accelerating therapeutic and diagnostic programs from concept to clinic.
Get in TouchOur Mission
Frameshift starts and builds life sciences companies. We work both internally and with external investigators, scientists, entrepreneurs, and investors to develop and advance therapeutic and diagnostic programs, primarily for human health.
We are based in Austin, Texas with operations in the San Francisco Bay Area and Central America.
Our Companies
Epiclone
Developing high-precision immuotherapies for cancer applications.
FB
Foundation Bio
Generating the biochemical data needed to power the next generation of foundation models.
Angstrom Bio
Developer of amplicon sequencing technologies for the rapid and cost-effective detection of rare variants in infectious disease and oncology.
Affigen
Affigen developed personalized - from discovery through dosing - monoclonal antibodies against patient-specific, tumor-specific targets in the hematological malignancies.
Tropicalis Pharmaceuticals
Formed in partnership with Clarus Ventures (now Blackstone Life Sciences) to develop safe and effective treatments for Neglected Tropical Diseases.